<unk>  is approved for use in combination with vemurafenib for the treatment of advanced melanoma with BRAF mutation (either V600E or V600K) that cannot be removed by surgery or which has metastasized. In the European Union,<unk>  is indicated for use in combination with vemurafenib for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation. Atezolizumab in combination with<unk>  and vemurafenib is indicated for the treatment of people with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Cobimetinib
Binimetinib
Selumetinib
Pralsetinib
Lestaurtinib
Nilotinib
Luspatercept
Gefitinib